In response, Vanda argued that the Future Pak offer "significantly" undervalued the company. To ward off the unwanted ...

When the FDA comes knocking at your drug manufacturing facility, it’s best to play along. | In an eight-observation Form 483, ...

While many campaigns for plaque psoriasis treatments focus on erasing the external effects of the condition, Sun Pharma’s ...

Some slap-downs from the PMCPA hit harder than others. The U.K. drug marketing body twisted the knife in its latest ruling ...

Deerfield Agency has opened its wallet again, buying up healthcare marketing and advertising firm Embedded to further extend ...

Ashkenazi takes over for Ruth Porat, who has been Alphabet’s longest-tenured CFO since taking over the job in 2015. Porat, 66 ...

Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide ...

In the latest brand consolidation move under the Inizio umbrella, the company’s Inizio Engage unit has combined two of its ...

The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon ...

With legislative efforts to combat drug shortages picking up and amid a record high numbe | A report from U.S. Pharmacopeia ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. | AbbVie is once again the ...

The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost ...